SCHEMBL24677009

SCHEMBL24677009

Cn1c(=O)cc(Cl)c2cc(-n3ccnc3)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.48
NOTUM Q6P988 1/20 0.45
ADH5 P11766 2/20 0.43
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
CYP19A1 P11511 3/20 0.41
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
CYP3A4 P08684 3/20 0.40
BAZ2B Q9UIF8 1/20 0.40
CRBN Q96SW2 2/20 0.40
PDE3B Q13370 2/20 0.40
PDE3A Q14432 2/20 0.40
TBXAS1 P24557 1/20 0.40
CYP2D6 P10635 2/20 0.39
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24677007 0.84 IDO1 (0.42) IDO1NOTUMPRMT5WDR77CYP19A1
SCHEMBL29769795 0.78 PIM1 (0.40) IDO1ADH5CYP3A4CYP2D6MAPT
SCHEMBL30833265 0.77 CYP11B1 (0.55) IDO1CYP19A1CYP11B1CYP11B2CYP3A4
SCHEMBL29769805 0.75 CYP1A2 (0.42) IDO1NOTUMCYP3A4CYP2D6MAPT
SCHEMBL16126788 0.75 CYP11B1 (0.53) IDO1NOTUMCYP19A1CYP11B1CYP11B2
SCHEMBL22078064 0.75 ADH5 (0.53) IDO1ADH5CYP3A4BAZ2BTBXAS1
SCHEMBL29769796 0.73 CD38 (0.47) PRMT5WDR77PDE3BPDE3A
SCHEMBL24676901 0.71 CNR1 (0.47) IDO1
SCHEMBL829894 0.70 KDM4E (0.47) IDO1MAPTLMNAALDH1A1HTT
SCHEMBL22078072 0.70 ADH5 (0.53) ADH5CYP3A4BAZ2BTBXAS1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117580829-A Quinoline and azaquinolines as inhibitors of CD38 勃林格英格翰国际有限公司 2024-02-20 CN disclosed
EP-4284511-A1 QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 Boehringer Ingelheim International GmbH (DE) 2023-12-06 EP disclosed
WO-2022165114-A1 QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 RIBON THERAPEUTICS, INC. (US) 2022-08-04 WO disclosed
US-20220242862-A1 QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220242862-A1 QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 CD38, NQO2, NQO1 IDO1 1082/4885NOTUM 3869/4885ADH5 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.